Advice

Following a resubmission

aliskiren (Rasilez) is not recommended for use within NHS Scotland for the treatment of essential hypertension.

Aliskiren has shown comparable efficacy to other antihypertensive agents in terms of blood pressure reduction, though its effects on mortality and long-term morbidity are currently unknown.

The manufacturer did not present a sufficiently robust clinical or economic analysis to gain acceptance by the SMC for the position sought.

Download detailed advice96KB (PDF)

Download

Medicine details

Medicine name:
aliskiren (Rasilez)
SMC ID:
462/08
Indication:
Essential Hypertension
Pharmaceutical company
Novartis Pharmaceuticals UK Ltd
BNF chapter
Cardiovascular system
Submission type
Resubmission
Status
Not recommended
Date advice published:
08 February 2010